| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 104.841 | 104.156 | 107.565 | 122.641 | 133.562 | 147.064 | 173.610 | 210.834 | 252.028 | 251.049 |
| Total Income - EUR | 105.813 | 105.094 | 107.971 | 123.277 | 133.617 | 147.483 | 173.614 | 214.041 | 252.033 | 251.052 |
| Total Expenses - EUR | 101.749 | 106.899 | 108.307 | 119.164 | 126.623 | 139.080 | 163.193 | 198.986 | 246.641 | 245.849 |
| Gross Profit/Loss - EUR | 4.064 | -1.804 | -336 | 4.113 | 6.994 | 8.403 | 10.421 | 15.055 | 5.392 | 5.203 |
| Net Profit/Loss - EUR | 3.415 | -1.804 | -1.319 | 2.889 | 5.658 | 7.122 | 8.720 | 14.081 | 3.578 | -1.703 |
| Employees | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
Check the financial reports for the company - Pharmacon 99 Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 960 | 741 | 5.961 | 5.582 | 7.166 | 7.030 | 7.353 | 56.935 | 44.189 | 31.439 |
| Current Assets | 27.731 | 22.415 | 24.695 | 32.913 | 39.293 | 35.900 | 40.796 | 51.798 | 47.998 | 50.350 |
| Inventories | 13.095 | 13.866 | 15.351 | 16.124 | 17.538 | 19.134 | 19.681 | 24.821 | 25.541 | 29.029 |
| Receivables | 6.381 | 2.660 | 6.476 | 10.566 | 9.348 | 11.202 | 11.956 | 19.388 | 13.741 | 13.646 |
| Cash | 8.255 | 5.888 | 2.867 | 6.223 | 12.406 | 5.564 | 9.159 | 7.588 | 8.716 | 7.675 |
| Shareholders Funds | 13.080 | 7.762 | 6.311 | 9.084 | 14.566 | 15.879 | 18.688 | 27.454 | 30.949 | 29.073 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 15.611 | 15.394 | 24.345 | 29.411 | 31.893 | 27.051 | 29.461 | 81.279 | 61.239 | 52.717 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Pharmacon 99 Srl